ProfileGDS5678 / 1452055_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 89% 89% 91% 90% 92% 91% 90% 90% 90% 91% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.3204191
GSM967853U87-EV human glioblastoma xenograft - Control 27.4177591
GSM967854U87-EV human glioblastoma xenograft - Control 37.0046189
GSM967855U87-EV human glioblastoma xenograft - Control 47.2843789
GSM967856U87-EV human glioblastoma xenograft - Control 57.4395691
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.0470290
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.508892
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3795291
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2187590
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1955490
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2044990
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3872991
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3793591
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3433391